In the pediatric setting, STEC-HUS represents the vast majority of thrombotic microangiopathy cases (>80%) [2], and additional biological testing, such as monitoring the protease ADAMTS13 activity or complement investigations, are mostly decided depending on atypical clinical presentation or after exclusion of STEC infection. The gene discussed is ADAMTS13; the disease is thrombotic microangiopathy.